ROCS (Radiotherapy After Oesophageal Cancer Stenting) Study (ROCS)
Palliative Radiotherapy in Addition to Self-expanding Metal Stent for Improving Dysphagia and Survival in Advanced Oesophageal Cancer: ROCS (Radiotherapy After Oesophageal Cancer Stenting) Study.
Sponsor: Lisette Nixon
A PHASE3 clinical study on Oesophageal Cancer, this trial is completed. The trial is conducted by Lisette Nixon and has accumulated 8 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jul 2019 — Jan 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 3 earlier versions
-
Oct 2018 — Jul 2019 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE3
First recorded
Oct 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Lisette Nixon
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bangor, United Kingdom , Bristol, United Kingdom , Cardiff, United Kingdom , Doncaster, United Kingdom , Dundee, United Kingdom , Middlesbrough, United Kingdom , Newport Gwent, United Kingdom , Nuneaton, United Kingdom , Rhyl, Denbighshire, United Kingdom , Saint Leonards-on-Sea, United Kingdom and 6 more locations